Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 3/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.43 |
| ▸ | NOS2 | P35228 | 5/20 | 0.42 |
| ▸ | NOS1 | P29475 | 4/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3633983 | 0.94 | CDK1 (0.44) | NOS2NOS1NOS3MAP4K4CDK1 | |
| SCHEMBL3634779 | 0.89 | NOS2 (0.45) | NOS2NOS1NOS3MAP4K4 | |
| SCHEMBL3630503 | 0.86 | JAK1 (0.45) | NOS2NOS1NOS3MAP4K4CDK1 | |
| SCHEMBL3811960 | 0.84 | PTPN1 (0.42) | NOS2NOS1NOS3MAP4K4 | |
| SCHEMBL3811876 | 0.84 | JAK1 (0.43) | NOS2NOS1NOS3MAP4K4 | |
| SCHEMBL3631872 | 0.82 | KDM4E (0.44) | NOS2NOS1NOS3MAP4K4 | |
| SCHEMBL3810048 | 0.81 | L3MBTL1 (0.48) | — | |
| SCHEMBL3635704 | 0.80 | MAPK8 (0.44) | NOS2NOS1NOS3MAP4K4 | |
| SCHEMBL3637372 | 0.80 | SYK (0.41) | NOS2NOS1NOS3MAP4K4 | |
| SCHEMBL2792593 | 0.79 | HCAR3 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155687-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | VIA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2008141976-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | GNAI3 601/4885GNAI1 487/4885GNAO1 919/4885 |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | GNAI3 601/4885GNAI1 487/4885GNAO1 919/4885 |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | GNAI3 601/4885GNAI1 487/4885GNAO1 919/4885 |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | GNAI3 601/4885GNAI1 487/4885GNAO1 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.